422 related articles for article (PubMed ID: 30556750)
1. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
Zhang B; Ma Z; Tan B; Lin N
Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
[TBL] [Abstract][Full Text] [Related]
2. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
3. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
5. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
6. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
7. A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
Choi EJ; Jung BJ; Lee SH; Yoo HS; Shin EA; Ko HJ; Chang S; Kim SY; Jeon SM
Oncogene; 2017 Sep; 36(37):5285-5295. PubMed ID: 28504720
[TBL] [Abstract][Full Text] [Related]
8. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
9. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
11. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
12. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
15. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
16. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
17. The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism.
Song MY; Lee DY; Chun KS; Kim EH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922165
[TBL] [Abstract][Full Text] [Related]
18. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
19. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway.
Zhou Y; Jiang Z; Lu H; Xu Z; Tong R; Shi J; Jia G
Chem Biodivers; 2019 Nov; 16(11):e1900400. PubMed ID: 31482617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
